The FTC has agreed to allow Amgen to buy Horizon, the manufacturer of Tepezza, after proposing a consent decree which seeks to prevent the company from gaining an overwhelming advantage…
The FTC has filed a complaint to stop Amgen from acquiring Horizon Therapeutics, saying it would give the manufacturer a monopoly on certain drugs, like Tepezza.
Two investors have filed lawsuits to stop the acquisition of Tepezza manufacturer Horizon Therapeutics, claiming the company is hiding material financial projections from shareholders who must approve the deal.
Despite the threat of having to eventually pay Tepezza lawsuit payouts, Amgen has acquired the drug's manufacturer, Horizon Pharmaceuticals for nearly $30 billion.
The FDA warns Prolia has been linked to dangerously low calcium blood levels.
A new case report warns that Prolia discontinuation can lead to vertebral fractures in bone cancer patients.
Prolia side effects may increase the risk of vertebral fractures after patients discontinue use, according to an Israeli study.
Public Citizen is calling for more stringent warnings on the osteoporosis drug Prolia, saying it is linked to an increased risk of vertebral fractures once patients stop using it.
A new study warns that Kyprolis heart problems may be more widespread than previously believed.
A new class of cholesterol drugs that includes Repatha and Praluent may be significantly overpriced in the U.S. when you look at the benefits they provide, according to the findings…
